You are here: Home » News-CM » Companies » News
Business Standard

Dr Reddys Laboratories launches Daptomycin for Injection in US market

Capital Market 

announced the launch of for Injection, 500mg/single-dose vial, a therapeutic equivalent generic version of Cubicin for Injection, approved by the


Cubicin for Injection (for injection) brand and generic had U. S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health.

Dr. Reddy's for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin. Cubicin is a trademark of Sharp & Dahme Corp.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, May 15 2019. 10:19 IST